← Research lines
L10

Senolytics and ovarian aging

Emerging therapies with high IP potential. Senescent cells in the ovary, dasatinib+quercetin, fisetin, and synergy with NAD+.

StatusCompleted
PriorityMedium
Progress6/6 subtopics
Depends onL5, L7, L9

Subtopics

  1. 10.1
    Senescent cells in the ovary and SASP
    Completed Thu Sep 24 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · View report →
  2. 10.2
    Dasatinib + quercetin: preclinical evidence
    Completed Sat Sep 26 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · View report →
  3. 10.3
    Fisetin as a natural senolytic
    Completed Mon Sep 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · View report →
  4. 10.4
    Therapeutic window for senolytics
    Completed Wed Sep 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · View report →
  5. 10.5
    Senolytics + NAD+: proposed synergy
    Completed Fri Oct 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · View report →
  6. 10.6
    Ethical observational protocol design
    Completed Sun Oct 04 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · View report →

Published reports